ALK and lung cancer: Based on the results of KEYNOTE-158 clinical trial, pembrolizumab has been approved by FDA as the front-line therapy for advanced lung cancer patients who present high PD-L1 expressions (TPS > 50%) and who are diagnosed as EGFR or ALK wild-type [10].